dr. arend on fda approval of frontline bevacizumab in ovarian cancer
Published 6 years ago • 258 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
1:14
dr. arend on niraparib with bevacizumab in ovarian cancer
-
3:47
frontline bevacizumab strategies in ovarian cancer
-
4:03
upfront bevacizumab in advanced ovarian cancer
-
26:02
updates in ovarian cancer: frontline maintenance
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
6:03
gog-0218: frontline bevacizumab in ovarian cancer
-
1:18
dr. arend on the rationale of novel combinations in gynecologic cancer
-
7:09
biomarker-driven frontline ovarian cancer treatment
-
7:24
ovarian cancer: maintenance following frontline bevacizumab
-
4:54
bevacizumab in recurrent ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
1:08
dr. burger on the use of bevacizumab in ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
1:09
dr. arend on unmet needs in platinum-resistant ovarian cancer
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
7:44
frontline treatments in ovarian cancer